New drug combo before surgery may boost cancer fight

NCT ID NCT07507968

First seen Apr 04, 2026 · Last updated May 23, 2026 · Updated 8 times

Summary

This study tests giving a combination of chemotherapy and an immunotherapy drug (durvalumab) before surgery, followed by more durvalumab after surgery, for people with stomach or esophagus cancer that can be removed. The goal is to see if this approach leads to a complete disappearance of cancer cells in the removed tissue. About 101 adults with locally advanced cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Caritas Klinikum Saabrücken

    Saarbrücken, Germany

    Contact

  • Charité Berlin

    Berlin, Germany

    Contact

  • HOPE Hamburg Eppendorf

    Hamburg, Germany

    Contact

  • Hospital Clínico Universitario de Valencia Servicio de Oncología Médica

    Valencia, Spain

    Contact

  • Hospital General Universitari Vall d'Hebron (HUVH)

    Barcelona, Spain

    Contact

  • Hospital Regional Universitario de Jaén

    Jaén, Spain

    Contact

  • Hospital Regional Universitario de Málaga

    Málaga, Spain

    Contact

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Spain

    Contact

  • Hospital Universitario Central de Asturias. Oncología Médica

    Oviedo, Spain

    Contact

  • Hospital Universitario Miguel Servet Oncología Médica

    Zaragoza, Spain

    Contact

  • Hospital Universitario Virgen de las Nieves de Granada

    Granada, Spain

    Contact

  • Hospital Universitario de Navarra (HUN)

    Pamplona, Spain

    Contact

  • Klinikum Essen Mitte

    Essen, Germany

    Contact

  • Krankenhaus Nordwest

    Frankfurt am Main, Germany

    Contact

  • Marien Hospital Herne

    Herne, Germany

    Contact

  • NCT Heidelberg

    Heidelberg, Germany

    Contact

  • Nürnberg Klinikum Nord

    Nuremberg, Germany

    Contact

  • RKH Klinikum Ludwigsburg

    Ludwigsburg, Germany

    Contact

  • TU München

    München, Germany

    Contact

  • UKE Hamburg

    Hamburg, Germany

    Contact

  • Universitätsklinikum Halle (Saale)

    Halle, Germany

    Contact

  • Universitätsklinikum Köln

    Cologne, Germany

    Contact

  • Universitätsklinikum Leipzig

    Leipzig, Germany

    Contact

  • Universitätsklinikum Marburg

    Marburg, Germany

    Contact

  • Universitätsklinikum Ulm

    Ulm, Germany

    Contact

  • Universitätsmedizin Göttingen

    Göttingen, Germany

    Contact

  • Universitätsmedizin Mainz

    Mainz, Germany

    Contact

  • Universitätsmedizin Mannheim

    Mannheim, Germany

    Contact

  • Vivantes Klinikum Neukölln

    Berlin, Germany

    Contact

Conditions

Explore the condition pages connected to this study.